TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant female aged ≥ 18 years old.~2. Subject is pregnant for at least 3 months, inclusive.~3. Subject is willing and able to adhere to visit schedules and all study requirements.~4. Subject has read and signed the study-specific informed consent.~Exclusion Criteria:~1. Subject with previous complicated pregnancy or preterm delivery, spontaneous or medical abortion;~2. Subject with history or concurrent high risk of dangerous gestation such as gestational diabetes mellitus (GDM), pregnant induced hypertension, or preeclampsia;~3. Subject received any influenza vaccine within the previous 6 months;~4. Subject has a history of hypersensitivity to eggs or egg protein or similar pharmacological effects to study vaccine;~5. Subject or her family has the history of Guillain-Barré Syndrome;~6. Subject has current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours;~7. Subject with influenza-like illness as defined by the presence of fever (temperature over 38ºC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;~8. Subject receive any treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;~9. Subject has immunodeficiency or is under immunosuppressive treatment.~10. Subject received any vaccine within 1 week prior to study vaccination or expected to receive one within 1 week after study vaccination;~11. Subject received any blood products, including immunoglobulin, in the past 3 months before consent;~12. Subject has underlying condition in the investigators' opinion may interfere with evaluation of the vaccine;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine in the Treatment of Postoperative Pain of Impacted Third Molar Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lower third molars impacted bilaterally requiring an osteotomy for their extraction and which are located spatially within the following positions or classes according to Pell \& Gregory (1933).~  * Position B (occlusal plane of the impacted tooth between the occlusal plane and the cervical line of the second molar).~ * Position C (tooth impacted below the cervical line of the second molar).~ * Class II (space between the second molar and the mandibular branch smaller than the distal mesial diameter of the third molar).~ * Class III (All or most of the third molar is inside the mandibular branch).~* Systemically healthy patients (ASA I-II).~Exclusion Criteria:~We exclude patients who present a history of infectious processes in the abscess area of third molars or who, for medical reasons, chronically use some type of analgesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Bupivacaine solution (Type: EXPERIMENTAL): In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
- Saline solution (Type: PLACEBO_COMPARATOR): In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Female, age at least 18 years at the time of signing informed consent - Diagnosed with type 1 diabetes mellitus for at least 1 year prior to the day of screening - Treated with multiple daily subcutaneous insulin injections or continuous subcutaneous insulin infusion (CSII) or inhaled insulin for at least 90 days prior to the day of screening - The subject is planning to become pregnant within 12 months from randomisation and willing to undertake pre-pregnancy counselling or the subject is pregnant with an intrauterine singleton living foetus (gestational week 8 to 13 (+6 days)) without any observed anomalies at randomisation, confirmed by an ultrasound scan - HbA1c at screening below or equal to 8.0% (64 mmol/mol) by central laboratory Exclusion Criteria: - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening - Pregnant and having proteinuria as evaluated by urine protein-to-creatinine ratio above or equal to 300 mg/g in urine sample measured at screening - Subject being treated or became pregnant with assistance of in vitro fertilisation or other medical infertility treatment - Receipt of any concomitant medication contraindicated in pregnancy according to local label within 28 days before screening and between screening and randomisation for non-pregnant subjects and 28 days before conception and between conception and randomisation for pregnant subjects - Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or pharmacologically dilated fundoscopy performed within the past 90 days prior to randomisation for non-pregnant subjects or within 28 days prior to randomisation for pregnant subjects. - History of severe hyperemesis gravidarum (requiring hospitalisation)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Degludec (Type: EXPERIMENTAL): Insulin Degludec once daily and Insulin Aspart 2-4 times daily
- Insulin Determir (Type: ACTIVE_COMPARATOR): Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* A male or female adult between 18 and 50 years of age.~* Written informed consent.~* Free of obvious health problems as established by medical history and history- directed physical examination before entering the study.~* Expected continuous residence in India during study period, without travel outside India~* An efficacious method of contraception must be used during the study for women of childbearing potential.~Exclusion Criteria:~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding administration of SA14-14-2 vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition.~* A family history of congenital or hereditary immunodeficiency.~* Any antiviral drug therapy within a period of six months before vaccination or at any time during the study period.~* History of significant allergic disease or reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.~* History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine.~* History of documented JE infection.~* Detectable anti JE or West Nile neutralizing antibodies in screening tests.~* Acute disease at the time of enrollment. Entry into the study may be deferred until the illness is resolved.~* Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurological or renal functional abnormality, as determined by history and physical or laboratory examination that is not controlled by drugs.~* Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.~* Seropositive for HIV, HCV or HbsAg.~* Lactation, pregnancy or intention to get pregnant.~* History of excessive alcohol consumption, drug abuse or significant psychiatric illness.~* Any other condition that in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): Single dose live attenuated Japanese encephalitis vaccine SA14-14-2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Temperature Management During Cryo AF Ablation (EnsoETM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients above the age of 18 years old.~2. Patients with the diagnosis of atrial fibrillation undergoing clinically indicated de-novo AF ablation procedure.~3. Patients must be willing to provide informed consent.~Exclusion Criteria:~1. Patients with contraindication to EGD.~2. History of prior AF ablation procedures.~3. Significant co-morbidities that preclude standard ablation procedure.~4. Patient is ineligible for EnsoETM placement due to:~   * Known esophageal deformity or evidence of esophageal trauma (for example history of esophagectomy, previous swallowing disorders, achalasia).~  * Known ingestion of acidic or caustic poisons within the prior 24 hours.~  * Patients with \<40 kg of body mass.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Placement of study device (EnsoETM) for temperature management
- Control (Type: ACTIVE_COMPARATOR): Placement of standard temperature probe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. established influenza A or B infection by virologic tests~2. age \>/=18 years~3. present within 4 days from illness onset~4. clinical evidence of LRTI and require hospital care~5. require antiviral (oseltamivir) treatment~6. able to provide written, informed consent.~Exclusion Criteria:~1. patients on immunosuppressants~2. pregnant or lactating woman~3. known hepatic failure, end-stage renal failure, cardiac arrhythmia (e.g. prolonged corrected QT interval \>450 msec)~4. known contraindications to azithromycin (e.g. allergic reaction)~5. lack of consent for study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Macrolide treatment (Type: EXPERIMENTAL): Azithromycin 500 mg daily for 5 days
- No macrolide treatment (Type: NO_INTERVENTION): No azithromycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For participants 50 years of age or older: any underlying chronic illness must be in stable condition~* For participants 2 to 49 years of age: participant has an increased risk for pneumococcal disease as a result of one of the following: chronic cardiovascular disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell anemia, living in a special environment or social setting such as crowded, closed communities~* Male, or female not of reproductive potential, or female of reproductive potential who agrees to remain abstinent or to use 2 acceptable methods of contraception through 6 weeks after study vaccination~Exclusion Criteria:~* Received prior vaccination with pneumococcal vaccine~* Has known or suspected immune dysfunction or conditions associated with immunosuppression, or is receiving immunosuppressive chemotherapy, including long-term systemic corticosteroids~* Has history of autoimmune disease~* Received a licensed live virus vaccine within 3 months before or is scheduled within 3 months after study vaccination~* Received a licensed inactivated vaccine within 28 days before or is scheduled within 28 days after study vaccination~* Received an investigational drug or other investigational vaccine within 2 months before or is scheduled within 28 days after study vaccination (3 months if a live virus vaccine)~* Received any blood product or immunoglobulin preparation within 6 months before or 28 days after study vaccination~* Hospitalized for acute illness within 3 months before study vaccination~* Is a pregnant woman or nursing mother~* History of invasive pneumococcal disease or of other culture-positive pneumococcal disease~* History of fever illness within 3 days before study vaccination~* Received antibiotic therapy for any acute illness within 7 days before study vaccination~* Hypersensitivity to any components of the vaccine, including phenol

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pneumovax™ 23: Participants Between 2 and 49 Years (Type: EXPERIMENTAL): Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
- Pneumovax™ 23: Participants >=50 Years (Type: EXPERIMENTAL): Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Different Bupivacaine Concentrations in Pediatric Patients Undergoing Transversus Abdominis Plane Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) status I/II~* Children between 1 to 8 years of age~* Patients undergoing unilateral inguinal hernia repair surgery~Exclusion Criteria:~* Denial of parents~* Patients who are allergic to local anesthetics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- TAP block with 1 mg.kg-1 bupivacaine 0.25% (Type: ACTIVE_COMPARATOR): Patients had 1 mg.kg-1 bupivacaine 0.25% with US-guided TAP block
- TAP block with 1 mg.kg-1 bupivacaine 0.125% (Type: ACTIVE_COMPARATOR): Patients had 1 mg.kg-1 bupivacaine 0.125% with US-guided TAP block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Infusion of Paracetamol for Intrapartum Analgesia of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-35 years.~2. Primigravida.~3. The gestational age between 37- 42 weeks.~4. Patient seeking analgesia.~5. Single viable fetus.~6. Vertex presentation.~7. Spontaneous onset of labor.~8. 1st stage of labor with cervical dilatation 3-4 cm ( in active phase).~Exclusion Criteria:~1. Extreme of age (below 18-above 35).~2. Multiparity.~3. Multiple gestation.~4. Malpresentation.~5. Major degree of cephalopelvic disproportion.~6. Any medical disorder with pregnancy e.g., Rheumatic heart disease, Diabetes mellitus, Hypertension, Anemia.~7. Induction of labor.~8. Cervical dilatation exceeds exceeding 4 cm.~9. Use of any other kind of analgesia before recruitment in the study.~10. Scared uterus.~11. Fetal distress.~12. Antepartum hemorrhage.~13. Intrapartum bleeding.~14. Polyhydramnios.~15. Pre-mature rupture of membranes.~16. Intra uterine infections.~17. Hypersensitivity to paracetamol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- (1) Active (Paracetamol) arm: n=60 (Type: ACTIVE_COMPARATOR): (Paracetamol)
- (2) Placbo (Sterile water) arm: n=60 (Type: PLACEBO_COMPARATOR): Sterile water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18 or older~2. current smoking as defined by a validated tobacco use measure~3. laboratory confirmed HIV-infection; 3) residence in commuting distance to the Bronx, NY or Baltimore, MD~4. English language fluency~5. motivation to quit within the next 30 days~6. at least weekly Internet and email access~7. REALM literacy score of 19/66 or above, indicating reading level of at least 4-6 grade (PSFW content was written for this literacy level)~8. willingness to provide informed consent and undergo randomization.~Exclusion Criteria:~1. previous participation in any trial of Positively Smoke Free interventions or use of PSFW+~2. pregnancy~3. contraindication to nicotine replacement therapy~4. current participation in an active smoking cessation treatment (e.g., group therapy, use of pharmacotherapy)~5. PSFW+ seed users will be excluded~6. To avoid study condition contamination and to maintain the statistical independence of subject outcomes, otherwise eligible individuals who are spouses, partners, and/or roommates of study participants will be excluded.~All ineligible patients will receive a Positively Smoke Free smoking cessation brochure and will be encouraged to access nationally-available (free) quitline counseling.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Positively Smoke Free on the Web (PSFW+) (Type: EXPERIMENTAL): Participants were assigned to the multimodal PSFW+ interactive web-based behavioral intervention hosted within an online social network.~PSFW+: PSFW+ is an intensive eight session motivational/educational web-program, based on social cognitive theory, designed to promote cessation among HIV-infected smokers. It included a professionally administered social network/online support community.~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches
- American Heart Association Getting Healthy (AHA) (Type: PLACEBO_COMPARATOR): Participants were assigned to the AHA Getting Healthy web-based control intervention program (the AHA later changed in name from Getting Healthy to My Life's Check, Life's Simple 7~AHA: The AHA Getting Healthy website is an attention-matched, health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population~Nicotine polacrilex: All participants were offered a 3-month supply of nicotine patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete